1. Home
  2. PZG vs ALDX Comparison

PZG vs ALDX Comparison

Compare PZG & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paramount Gold Nevada Corp.

PZG

Paramount Gold Nevada Corp.

HOLD

Current Price

$1.45

Market Cap

132.1M

ML Signal

HOLD

Logo Aldeyra Therapeutics Inc.

ALDX

Aldeyra Therapeutics Inc.

HOLD

Current Price

$1.57

Market Cap

124.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PZG
ALDX
Founded
1992
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.1M
124.9M
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
PZG
ALDX
Price
$1.45
$1.57
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.50
AVG Volume (30 Days)
494.7K
891.5K
Earning Date
05-11-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
40.43
EPS
N/A
N/A
Revenue
$330,259.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$1.07
52 Week High
$2.70
$6.18

Technical Indicators

Market Signals
Indicator
PZG
ALDX
Relative Strength Index (RSI) 59.51 43.54
Support Level $1.07 $1.48
Resistance Level $1.46 $1.88
Average True Range (ATR) 0.09 0.08
MACD 0.02 0.01
Stochastic Oscillator 58.74 47.83

Price Performance

Historical Comparison
PZG
ALDX

About PZG Paramount Gold Nevada Corp.

Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, the company is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States. Also, it explores for gold and silver. The company enhances the value of projects by implementing exploration and engineering programs that are likely to expand and upgrade known mineralized material to reserves. Its projects include sleeper gold, grassy mountain gold, frost project, other non-material, and others.

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Share on Social Networks: